SPONSOR
Acepodia Biotech, Inc.
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2, Phase 1
Acepodia Biotech, Inc. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including IgG4 Related Disease, Locally Advanced Solid Tumor, Metastatic Solid Tumor.
The trial portfolio spans Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Acepodia Biotech, Inc.
How many clinical trials has Acepodia Biotech, Inc. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Acepodia Biotech, Inc., of which 2 are actively recruiting participants. These trials cover conditions including IgG4 Related Disease, Locally Advanced Solid Tumor, Metastatic Solid Tumor. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Acepodia Biotech, Inc. research focus on?
Acepodia Biotech, Inc. clinical trials span IgG4 Related Disease, Locally Advanced Solid Tumor, Metastatic Solid Tumor. The research pipeline includes Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Acepodia Biotech, Inc. clinical trial?
To participate in a Acepodia Biotech, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Acepodia Biotech, Inc. trials with current recruitment status updated daily.
Clinical Trials by Acepodia Biotech, Inc.
NCT07061938 Phase 1, Phase 2
Recruiting
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
IgG4 Related Disease
NCT06415487 Phase 1
Recruiting
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Locally Advanced Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology